# Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

> **NCT02962414** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 206 (actual)

## Conditions studied

- Tuberous Sclerosis Complex

## Interventions

- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT02962414
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-08
- **Primary completion:** 2027-08-04
- **Final completion:** 2027-08-13
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02962414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02962414, "Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02962414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*